Analysts’ Viewpoint
Increase in the geriatric population and rise in prevalence of diabetes, obesity, and hypertension are driving the global congestive heart failure drugs market. Poor diet, sedentary lifestyle, and tobacco consumption could increase the risk of developing congestive heart failure (CHF). Furthermore, rise in healthcare expenditure, increase in awareness about heart health, and surge in access to healthcare services are expected to bolster market expansion during the forecast period.
Development of innovative treatments and technologies, such as implantable devices and stem cell therapy, for the treatment of CHF offers lucrative opportunities to market players. Manufacturers are focusing on launch of efficient and low cost products and services such as medications, medical devices, and surgical procedures to increase market share.
Congestive heart failure is a chronic condition, where the heart cannot pump enough blood to meet the body's needs. CHF drugs are used to manage the symptoms and improve the quality of life of patients. Major drug classes used to treat CHF are diuretics, ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, and digitalis. These drugs work by reducing the workload on the heart, improving blood flow, and preventing the buildup of fluid in the lungs and other parts of the body.
Heart failure, also known as congestive heart failure, is a medical condition, in which the heart is unable to pump enough blood to meet the body's needs. It is a chronic and progressive condition that affects millions of people globally. According to the American Heart Association, the prevalence of heart failure is increasing, and affects nearly 6.5 million people aged 20 years and older in the U.S. Rise in the prevalence of heart failure is propelling the global congestive heart failure market size.
Aging population is another factor contributing to surging in prevalence of heart failure. Risk of developing heart failure increases as people age. The aging baby boomer population, in particular, is expected to contribute significantly to rise in prevalence of heart failure. Increase in incidence of obesity and diabetes is another factor contributing to rising in the prevalence of heart failure.
Technological advancements in drug development are driving the global congestive heart failure drugs market. These advancements are enabling the identification of new drug targets and biomarkers for CHF, which could lead to development of more effective and targeted therapies. For instance, advances in genetics and molecular biology have enabled researchers to identify specific genes, proteins, and signaling pathways involved in the development and progression of congestive heart failure. This has led to the development of drugs that target these specific molecules or pathways, such as angiotensin receptor blockers, which affect the renin-angiotensin system.
Technological advancements are improving drug discovery and development processes. High-throughput screening methods, which use robotics and automation to quickly test large number of compounds, have accelerated the drug discovery process. Advances in computational modeling and simulation are helping researchers to design and optimize drug candidates more efficiently, thereby reducing the time and costs involved in drug development.
Technological advancements are also enhancing the delivery of congestive heart failure drugs to patients. Development of nanotechnology-based drug delivery systems has enabled targeted delivery of drugs to specific tissues or cells, thus improving drug efficacy and reducing side effects. Furthermore, usage of implantable devices such as pacemakers and implantable cardioverter-defibrillators (ICDs) are helping to manage the symptoms of congestive heart failure and reduce the risk of sudden cardiac death.
In terms of type of congestive heart failure, the left-sided heart failure segment accounted for largest global congestive heart failure drugs market share in 2022. This is ascribed to higher prevalence compared to right-sided heart failure. Additionally, left-sided heart failure can lead to more severe symptoms and complications, which could require more aggressive treatment with medication.
Based on drug class, the ACE inhibitors segment dominated the global market in 2022. ACE inhibitors are highly effective in reducing the symptoms and progression of the disease. Numerous clinical trials have shown that ACE inhibitors can reduce hospitalizations and mortality rates in CHF patients. These are also well-tolerated and have a relatively low risk of side effects compared to other CHF drugs. ACE inhibitors are available in generic forms, which are much cheaper than branded drugs, making them accessible to a wider patient population. Additionally, long-term usage of ACE inhibitors is cost-effective, as these can help prevent hospitalization and other expensive medical procedures associated with CHF.
In terms of distribution channel, the retail pharmacies segment held the leading share of the global congestive heart failure drugs market in 2022. Retail pharmacies are easily accessible to patients and are spread across various geographies. This makes it convenient for CHF patients to purchase medications easily and regularly, without having to travel far or face any logistical difficulties.
Retail pharmacies offer a range of CHF medications from different manufacturers, giving patients the opportunity to compare prices and choose the most affordable option. These channels have strong relationships with health insurance providers, which enables them to provide patients with insurance coverage information, co-pay assistance programs, and other cost-saving measures. This can be a significant advantage for CHF patients, as the cost of medication can be a major barrier to accessing and adhering to treatment.
As per congestive heart failure drugs industry trends, North America accounted for the leading share of the global market in 2022. This is ascribed to high prevalence of heart diseases, well-developed healthcare infrastructure, and increase in investment in research & development activities in the region. According to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases claim the life of one individual in the U.S. every 34 seconds. Furthermore, heart diseases accounted for approximately 697,000 deaths in the country in 2020, which equates to one in every five fatalities.
The market is Europe is driven by surge in prevalence of CHF, aging population, and development of novel therapies. Pharmaceutical companies are investing significantly in research & development to bring innovative therapies and drugs to market. For example, Entresto, a novel drug developed by Novartis, has been shown to improve patient outcomes in clinical trials and has received regulatory approval in Europe. Additionally, there has been a growing interest in precision medicine for CHF, with the usage of biomarkers and genetic testing to tailor treatments to individual patients.
The global market is fragmented, with the presence of large number of players. Companies in the congestive heart failure drugs market are Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen, Inc., Boehringer Ingelheim International GmbH., Pfizer, Inc., Johnson & Johnson Services, Inc., and Eli Lilly and Company. Major players have adopted strategies such merger & acquisition, collaboration, and portfolio expansion to increase market share and presence.
Each of these players in the congestive heart failure drugs market has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 6.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 13.5 Bn |
|
CAGR |
7.6% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
The global industry was valued at US$ 6.7 Bn in 2022
It is projected to reach more than US$ 13.5 Bn by 2031
The CAGR is anticipated to be 7.6% from 2023 to 2031
The ACE inhibitors segment held more than 50.0% share in 2022
North America is expected to account for significant share from 2022 to 2031
Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen, Inc., Boehringer Ingelheim International GmbH., Pfizer, Inc., Johnson & Johnson Services, Inc., and Eli Lilly and Company are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Congestive Heart Failure Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Congestive Heart Failure Drugs Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. Pipeline Analysis
5.3. Heart Failure Diseases Prevalence: Overview
6. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Type of Digestive Heart Failure
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
6.3.1. Left-sided Heart Failure
6.3.2. Right-sided Heart Failure
6.3.3. High-output Heart Failure
6.4. Market Attractiveness Analysis, by Type of Digestive Heart Failure
7. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. ACE Inhibitors
7.3.2. Angiotensin-2 Receptor Blockers
7.3.3. Beta Blockers
7.3.4. Mineralocorticoid Receptor Antagonists
7.3.5. Diuretics
7.3.6. Ivabradine
7.3.7. Sacubitril Valsartan
7.3.8. Others (digoxin etc.)
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospitals Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Congestive Heart Failure Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
10.2.1. Left-sided Heart Failure
10.2.2. Right-sided Heart Failure
10.2.3. High-output Heart Failure
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. ACE Inhibitors
10.3.2. Angiotensin-2 Receptor Blockers
10.3.3. Beta Blockers
10.3.4. Mineralocorticoid Receptor Antagonists
10.3.5. Diuretics
10.3.6. Ivabradine
10.3.7. Sacubitril Valsartan
10.3.8. Others (digoxin etc.)
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospitals Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type of Digestive Heart Failure
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Congestive Heart Failure Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
11.2.1. Left-sided Heart Failure
11.2.2. Right-sided Heart Failure
11.2.3. High-output Heart Failure
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. ACE Inhibitors
11.3.2. Angiotensin-2 Receptor Blockers
11.3.3. Beta Blockers
11.3.4. Mineralocorticoid Receptor Antagonists
11.3.5. Diuretics
11.3.6. Ivabradine
11.3.7. Sacubitril Valsartan
11.3.8. Others (digoxin etc.)
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospitals Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type of Digestive Heart Failure
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
12.2.1. Left-sided Heart Failure
12.2.2. Right-sided Heart Failure
12.2.3. High-output Heart Failure
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. ACE Inhibitors
12.3.2. Angiotensin-2 Receptor Blockers
12.3.3. Beta Blockers
12.3.4. Mineralocorticoid Receptor Antagonists
12.3.5. Diuretics
12.3.6. Ivabradine
12.3.7. Sacubitril Valsartan
12.3.8. Others (digoxin etc.)
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospitals Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type of Digestive Heart Failure
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Congestive Heart Failure Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
13.2.1. Left-sided Heart Failure
13.2.2. Right-sided Heart Failure
13.2.3. High-output Heart Failure
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. ACE Inhibitors
13.3.2. Angiotensin-2 Receptor Blockers
13.3.3. Beta Blockers
13.3.4. Mineralocorticoid Receptor Antagonists
13.3.5. Diuretics
13.3.6. Ivabradine
13.3.7. Sacubitril Valsartan
13.3.8. Others (digoxin etc.)
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospitals Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type of Digestive Heart Failure
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Congestive Heart Failure Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
14.2.1. Left-sided Heart Failure
14.2.2. Right-sided Heart Failure
14.2.3. High-output Heart Failure
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. ACE Inhibitors
14.3.2. Angiotensin-2 Receptor Blockers
14.3.3. Beta Blockers
14.3.4. Mineralocorticoid Receptor Antagonists
14.3.5. Diuretics
14.3.6. Ivabradine
14.3.7. Sacubitril Valsartan
14.3.8. Others (digoxin etc.)
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospitals Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type of Digestive Heart Failure
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Novartis AG
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. AstraZeneca
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Amgen, Inc.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Boehringer Ingelheim International GmbH
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Pfizer, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Johnson & Johnson Services, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Eli Lilly and Company
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
List of Tables
Table 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031
Table 02: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 03: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031
Table 07: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 08: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031
Table 11: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 12: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031
Table 15: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 16: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031
Table 19: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 20: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Type Congestive Heart Failure Drugs, 2017‒2031
Table 23: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 24: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Congestive Heart Failure Drugs Market Value Share, by Type of Congestive Heart Failure, 2022
Figure 03: Global Congestive Heart Failure Drugs Market Value Share, by Drug Class, 2022
Figure 04: Global Congestive Heart Failure Drugs Market Value Share, by Distribution Channel, 2022
Figure 05: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
Figure 06: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031
Figure 07: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Left-sided Heart Failure, 2017‒2031
Figure 08: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by Right-sided Heart Failure, 2017‒2031
Figure 09: Global Congestive Heart Failure Drugs Market Value (US$ Mn), by High-output Heart Failure, 2017‒2031
Figure 10: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
Figure 11: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031
Figure 12: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by ACE Inhibitors, 2017–2031
Figure 13: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Angiotensin-2 Receptor Blockers (ARBs or AIIRAs), 2017–2031
Figure 14: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Beta Blockers, 2017–2031
Figure 15: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Mineralocorticoid Receptor Antagonists, 2017–2031
Figure 16: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Diuretics, 2017–2031
Figure 17: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Ivabradine, 2017–2031
Figure 18: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Sacubitril Valsartan, 2017–2031
Figure 19: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by others (digoxin etc.), 2017–2031
Figure 20: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 21: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 22: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Hospitals Pharmacies, 2017–2031
Figure 23: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 24: Global Congestive Heart Failure Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 25: Global Congestive Heart Failure Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 26: Global Congestive Heart Failure Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 27: North America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 29: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 30: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
Figure 31: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031
Figure 32: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
Figure 33: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031
Figure 34: North America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 35: North America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Europe Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 38: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 39: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
Figure 40: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031
Figure 41: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
Figure 42: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031
Figure 43: Europe Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 44: Europe Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Asia Pacific Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 48: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
Figure 49: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031
Figure 50: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
Figure 51: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031
Figure 52: Asia Pacific Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 53: Asia Pacific Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Latin America Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 55: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 56: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 57: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
Figure 58: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031
Figure 59: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
Figure 60: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031
Figure 61: Latin America Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 62: Latin America Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 63: Middle East & Africa Congestive Heart Failure Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 64: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 65: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 66: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Type of Congestive Heart Failure, 2022 and 2031
Figure 67: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Type of Congestive Heart Failure, 2023–2031
Figure 68: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Drug Class 2022 and 2031
Figure 69: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Drug Class 2023–2031
Figure 70: Middle East & Africa Congestive Heart Failure Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 71: Middle East & Africa Congestive Heart Failure Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 72: Company Share Analysis, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Congestive Heart Failure Drugs Market
